Book a Meeting

Anti-ICOS Antibody, ADCC Enchanced (BioBet-CB-092LX) (CAT#: BioBet-CB-092LX) Datasheet

Target
ICOS
Isotype
IgG4
Description
Anti-ICOS Antibody, ADCC Enchanced (BioBet-CB-092LX) is a glycosylation-modified anti-ICOS therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced ICOS antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
ICOS
Full Name
Inducible T cell costimulator
Background
The protein encoded by this gene belongs to the CD28 and CTLA-4 cell-surface receptor family. It forms homodimers and plays an important role in cell-cell signaling, immune responses, and regulation of cell proliferation. [provided by RefSeq, Jul 2008]
Alternative Names
ICOS; inducible T cell costimulator
Gene ID
29851
UniProt ID
Q9Y6W8
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG4
Antibody Clone
BioBet-CB-092LX
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human ICOS (Feladilimab) Antibody is derived from clone Feladilimab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the ICOS, and it is intended for the research of Head and neck squamous cell carcinoma .
Antibody Indication
Head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma

Related Products

Anti-ICOS Antibody, Non-Fucosylated (BioBet-1019ZP) (CAT#: BioBet-1019ZP)
Anti-ICOS Antibody, Non-Fucosylated (BioBet-1023ZP) (CAT#: BioBet-1023ZP)
Anti-ICOS Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP580) (CAT#: AES-0622-ZP580)
Anti-ICOS Antibody, Half-Life Extended (AES-0622-ZP1236) (CAT#: AES-0622-ZP1236)
Anti-ICOS Antibody, On-Target (AES-0622-ZP908) (CAT#: AES-0622-ZP908)
Anti-ICOS Antibody, Non-Fucosylated (BioBet-1021ZP) (CAT#: BioBet-1021ZP)
Anti-ICOS Antibody, Non-Fucosylated (BioBet-1024ZP) (CAT#: BioBet-1024ZP)
Anti-ICOS Antibody, Non-Fucosylated (BioBet-1813ZP) (CAT#: BioBet-1813ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.